Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 6 | The Journal of Headache and Pain

Fig. 6

From: Increased TSPO alleviates neuropathic pain by preventing pyroptosis via the AMPK-PGC-1α pathway

Fig. 6

TSPO protected against mitochondrial dysfunction and pyroptosis by enhancing AMPK-PGC1α pathway. A Schematic diagram of the experimental flow. B Western blot showing the expression levels of TSPO, p-AMPK, AMPK, PGC-1α, MFN2 and TFAM after inhibition of AMPK. C Representative transmission electron microscopy images of mitochondria after inhibition of AMPK, scale bar = 2 μm. D, E ELISA results showing the levels of the IL-1β and the IL- after inhibition of AMPK, n = 6 per group. F Western blot showing the expression levels of NLRP3, Caspase-1 and GSDMD-N after inhibition of AMPK. G Representative immunofluorescence images showing c-Fos and NeuN co-staining after inhibition of AMPK. H Behavioral testing of von Frey after inhibition of AMPK at different time points (days 0, 3, 7, 14, and 21), n = 10 per group. Data are represented as mean ± SEM, ***p < 0.001

Back to article page